^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DNMT3A mutation

    i
    Other names: DNMT3A, DNA Methyltransferase 3 Alpha, DNA (Cytosine-5-)-Methyltransferase 3 Alpha, DNA (Cytosine-5)-Methyltransferase 3A, DNA MTase HsaIIIA, DNA Cytosine Methyltransferase 3A2, DNA Methyltransferase HsaIIIA, DNMT3A2, Dnmt3a
    Entrez ID:
    1788
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    almost1year
    Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis | NEJM Evidence https://t.co/d9nCUyf3Nz key features to look for single DNMT3A, high-risk mutations, two or more mutations, a VAF of 0.2 or more, 65 yrs or older, having CCUS vs CHIP, RBC indices. (@salmanf)
    DNMT3A (DNA methyltransferase 1)
    |
    DNMT3A mutation
    1year
    Happy to share one more collaborative effort led by Drs. Kapur and ⁦@sophpacz⁩ My lab contributed to this study on leukemia by defining the transcriptomic profile of human CD34+ HSPCs expressing DNMT3a mutation. #leukemia #epigenetics #PernaLab https://t.co/y5TnE7MPfK (@fabianaperna)
    DNMT3A (DNA methyltransferase 1) • CD34 (CD34 molecule)
    |
    DNMT3A mutation
    1year
    Some fun facts about CMML: TET2/SRSF2 mutations are initiating events but acquisition of ASXL-1, RUNX1, SF3B1 and DNMT3A mutations usually give rise to dysplastic CMML while ASXL1, JAK2 and RAS give rise to proliferative CMML. TP53 mutations are extremely rare in CMML ( <1%). (@Persian1010)
    TP53 (Tumor protein P53) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • RAS (Rat Sarcoma Virus)
    |
    TP53 mutation • DNMT3A mutation • TET2 mutation • SRSF2 mutation
    1year
    65-70 year old fit patient diagnosed with “MDS” in community due to 15% blasts in diagnostic BM Bx. NGS results NPM1, DNMT3A and IDH2 mutations c/w AML. Received 1 cycle of Aza in community before seeing you. Blood counts stable w/o circulating blasts. You recommend? (@LeukDocJZ)
    Clinical • Next-generation sequencing
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1)
    |
    IDH2 mutation • NPM1 mutation • DNMT3A mutation • DNMT3A mutation + IDH mutation
    over1year
    This is a subset of AML that has very high risk of relapse. This is data from our Center Much more for DNMT3A R882 than other DNMT3A mutations https://t.co/Uw6owzNIMT (@nvpatkar)
    DNMT3A (DNA methyltransferase 1)
    |
    DNMT3A mutation • DNMT3A R882
    over1year
    Leukemic and transplant experts! Otherwise healthy patient AML in CR1 after treatment with 7 plus 3 plus midostaurin. Mutation profile FLT3 ITD+/NPM1+/DNMT3A+. No detectable mutations on NGS panel after induction. Good MUDs available. Would anyone not transplant? (@AaronGoodman33)
    Clinical • Next-generation sequencing
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1)
    |
    FLT3-ITD mutation • NPM1 mutation • DNMT3A mutation
    |
    Rydapt (midostaurin)
    over1year
    The answer was angioimmunoblastic T-cell which often expresses CD10. Lymphoma of T-follicular helper cells. Often with mutations in TET2, DNMT3A, RHOA. Difficult to treat, optimal induction unknown CHOP CHOEP BC-CHP (if CD30+>10%) Consolidate with auto? Who knows. (@AaronGoodman33)
    DNMT3A (DNA methyltransferase 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • TET2 (Tet Methylcytosine Dioxygenase 2) • RHOA (Ras homolog family member A) • MME (Membrane Metalloendopeptidase)
    |
    DNMT3A mutation • TET2 mutation
    2years
    #Tandem22 #leusm Heuser: ELN recommends DAT (DNMT3A/ASXL1/TET2) mutations not be used to assess MRD because they are frequently present in pre-malignant clonal hematopoiesis. (@hemedoc)
    DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    DNMT3A mutation • ASXL1 mutation • TET2 mutation
    2years
    💼🔛acute myeloid leukemia w/ @DrPinkalDesai WATCH▶️https://t.co/0vplXNFi1Y ✅68yr in good health, WBC of 30k ✅ Dx w/AML➡️normal cytogenetics ✅Myeloid mutation panel➡️DNMT3A mutation ✅Treated➡️IDA/DNR + cytarabine, achieved MRD negative CR What is the next step in tx❓ (@managingmyeloma)
    Minimal residual disease
    |
    DNMT3A (DNA methyltransferase 1)
    |
    DNMT3A mutation
    |
    cytarabine
    2years
    MBD4 also an emerging risk for DNMT3A-mutated young onset acute myeloid leukemia! (@DNA_diva)
    DNMT3A (DNA methyltransferase 1) • MBD4 (Methyl-CpG Binding Domain 4, DNA Glycosylase)
    |
    DNMT3A mutation
    2years
    💼#AML w/ @DrPinkalDesai ☘️ What is the next step in tx❓ ➡️https://t.co/lpGsVfRT3P ✅6⃣8⃣ y/o pt ✅Good health➡️ w/WBC of 30,000 ✅Dx w/#AML w/normal cytogenetics ✅Myeloid mutation panel➡️DNMT3A mutation ✅Treated w/ 7⃣ & 3⃣ achieved MRD➖complete remission😀 @LeukemiaRF (@medical_medicom)
    Clinical
    |
    DNMT3A (DNA methyltransferase 1)
    |
    DNMT3A mutation
    2years
    💼🔛acute myeloid leukemia w/ @DrPinkalDesai WATCH▶️https://t.co/0vplXNFi1Y ✅68yr in good health, WBC of 30k ✅ Dx w/AML➡️normal cytogenetics ✅Myeloid mutation panel➡️DNMT3A mutation ✅Treated➡️IDA/DNR + cytarabine, achieved MRD negative CR What is the next step in tx❓ (@managingmyeloma)
    Minimal residual disease
    |
    DNMT3A (DNA methyltransferase 1)
    |
    DNMT3A mutation
    |
    cytarabine
    2years
    💼🔛acute myeloid leukemia w/ @DrPinkalDesai WATCH▶️https://t.co/0vplXNFi1Y ✅68yr in good health, WBC of 30k ✅ Dx w/AML➡️normal cytogenetics ✅Myeloid mutation panel➡️DNMT3A mutation ✅Treated➡️IDA/DNR + cytarabine, achieved MRD negative CR What is the next step in tx❓ (@managingmyeloma)
    Minimal residual disease
    |
    DNMT3A (DNA methyltransferase 1)
    |
    DNMT3A mutation
    |
    cytarabine
    over2years
    Donor clonal hematopoiesis with mutations in DNMT3A assoc with improved overall survival, reduced risk of relapse, and elevated risk of chronic GVHD. #gvhd #leusm #bmtsm #lymsm #mdssm https://t.co/j91yEK1JUk (@CyclingDoctor)
    Clinical
    |
    DNMT3A (DNA methyltransferase 1)
    |
    DNMT3A mutation
    over2years
    CHIP is associated with shorter PFS in non-transplanted #myeloma patients and its prevalence, particularly DNMT3A mutations, increases while on treatment. @theMMRF @ASH_hematology @getz_lab @IreneGhobrial @LabGhobrial @DanaFarberNews @DanaFarber #mmsm #MultipleMyeloma #ASH21 (@tarekmd91)
    Clinical
    |
    DNMT3A (DNA methyltransferase 1)
    |
    DNMT3A mutation
    over2years
    4⃣.,the HARMONY consortium compiled impressive data sets of hematologic cancer pts. Have a look at abstracts from the AML group led by Lars Bullinger: #608 on RAD21 co-mutaton in DNMT3A-mut AML, #3438 on Impact of Gender on Molecular AML Subclasses & #4041 on relapse risk in CR1 (@KlausMetzelerMD)
    Clinical
    |
    DNMT3A (DNA methyltransferase 1) • RAD21 (RAD21 Cohesin Complex Component)
    |
    DNMT3A mutation
    over2years
    A 6⃣8⃣ y/o pt ➡️➕ health presents w/white cell count of 30,000 diagnosed w/#AML w/normal cytogenetics. Myeloid mutation panel ➡️DNMT3A mutation. The pt is treated w/ 7⃣ & 3⃣ achieved MRD➖complete remission😀 What is the next step in tx❓@DrPinkalDesai ➡️https://t.co/lpGsVfRT3P (@medical_medicom)
    Clinical
    |
    DNMT3A (DNA methyltransferase 1)
    |
    DNMT3A mutation
    over2years
    A 6⃣8⃣ y/o pt ➡️➕ health presents w/white cell count of 30,000 diagnosed w/#AML w/normal cytogenetics. Myeloid mutation panel ➡️DNMT3A mutation. The pt is treated w/ 7⃣ & 3⃣ achieved MRD➖complete remission😀 What is the next step in tx❓@DrPinkalDesai ➡️https://t.co/lpGsVfRT3P (@medical_medicom)
    Clinical
    |
    DNMT3A (DNA methyltransferase 1)
    |
    DNMT3A mutation
    almost3years
    A 6⃣8⃣ y/o pt ➡️➕ health presents w/white cell count of 30,000 diagnosed w/#AML w/normal cytogenetics. Myeloid mutation panel ➡️DNMT3A mutation. The pt is treated w/ 7⃣ & 3⃣ achieved MRD➖complete remission😀 What is the next step in tx❓@DrPinkalDesai ➡️https://t.co/lpGsVfRT3P (@medical_medicom)
    Clinical
    |
    DNMT3A (DNA methyltransferase 1)
    |
    DNMT3A mutation
    almost3years
    A 6⃣8⃣ y/o pt ➡️➕ health presents w/white cell count of 30,000 diagnosed w/#AML w/normal cytogenetics. Myeloid mutation panel ➡️DNMT3A mutation. The pt is treated w/ 7⃣ & 3⃣ achieved MRD➖complete remission😀 What is the next step in tx❓@DrPinkalDesai ➡️https://t.co/lpGsVg9tVn (@medical_medicom)
    Clinical
    |
    DNMT3A (DNA methyltransferase 1)
    |
    DNMT3A mutation
    over3years
    Fascinating presentation on CH in older donors and effect on the graft , recipient survival and leukemia development. Summary of conclusions: Having a DNMT3A >1% mutation in older pts has no detrimental effect ( may have inc PFS) , no ⬆️ in AML. Other mutations esp germline IMP ! (@beatalleukemia)
    Clinical
    |
    DNMT3A (DNA methyltransferase 1)
    |
    DNMT3A mutation
    over3years
    And lastly, one could model the probability that a mutation in DNMT3A is in CHIP clone (common) vs. T-cell lymphoma (highly recurrent), compared to BTK mutation in CHIP clone (rare/unreported) vs B-cell lymphoma (highly recurrent). Context is key. (@dgermain21)
    DNMT3A (DNA methyltransferase 1) • BTK (Bruton Tyrosine Kinase)
    |
    DNMT3A mutation • BTK mutation
    over3years
    So, what did we find? Pretty cool. A patient with two DNMT3A mutations, a TET2 mutation, inversion 16, trisomy 8? Five totally independent clones (1 wildtype, 3 CHIP, 1 AML). DNMT3A and TET2 mutations were not related to his leukemia (@DrChrisHourigan)
    Clinical
    |
    DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    DNMT3A mutation • TET2 mutation